Abstract
Repeated daily administration of an endogenous trace amine, beta-phenylethylamine (PEA), produces behavioral sensitization such that the intensity of PEA-induced stereotyped behaviors in rats increases gradually during the treatment, and a challenge injection with PEA reinstates the enhanced stereotypy even long after withdrawal. In the present study, we examined the neurochemical changes in the central dopaminergic neuron systems in the rat for 7 drug-free days after repeated treatment with PEA (50 mg/kg, IP day for 14 or 28 days). During withdrawal, a decrease in steady-state levels of tissue dopamine (DA) and its metabolite, dihydroxyphenylacetic acid (DOPAC), was found in the mesolimbic DA nerve terminal areas of the rat brain receiving repeated PEA treatment. Fifteen minutes after challenge administration of PEA at varying doses from 6.3 to 75 mg/kg, the rats with repeated PEA treatment required smaller doses of PEA challenge than the rats with acute PEA treatment in order to obtain a significant decrease in striatal DOPAC content compared to the saline control in each treatment group. These results imply that the behavioral sensitization to PEA is accompanied by enduring modifications of the specific dopaminergic neuron systems in the rat brain. This suggestion was strongly supported by the results of the study using in vivo intracerebral dialysis, which indicated that 25 mg/kg PEA challenge elicited a remarkable increase in the extracellular DA concentrations in striatal perfusates collected from the PEA-pretreated rats, in accordance with the intensity of stereotyped behaviors. These findings argue that the hyper-responsiveness to PEA of the striatal dopaminergic neuron systems persists long after withdrawal from repeated treatment with PEA.
Similar content being viewed by others
Abbreviations
- PEA :
-
beta-phenylethylamine
- DA :
-
dopamine
- DOPAC :
-
dihydroxyphenylacetic acid
- HVA :
-
homovanillic acid
- HPLC-ECD :
-
high performance liquid chromatography with electrochemical detection
References
Bailey BA, Philips SR, Boulton AA (1987) In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudatus nucleus by phenylethylamine. Neurochem Res 12:173–178
Borison RL, Diamond BI (1978) A new animal model for schizophrenia: interaction with adrenergic mechanisms. Biol Psychiatry 13:217–225
Borison RL, Havdala HS, Diamond BI (1977) Chronic phenylethylamine stereotypy in rats: a new animal model for schizophrenia? Life Sci 21:117–122
Braestrup C, Randrup A (1978) Stereotyped behavior in rats induced by phenylethylamine, dependence on dopamine and noradrenaline, and possible relation to psychosis? In: Mosnaim AD, Wolf ME (eds) Non-catecholic phenylethylamine. Decker, New York, pp 245–269
Dourish CT (1981) Behavioral effects of acute and chronic β-phenylethylamine administration in the rat: evidence for the involvement of 5-hydroxytryptamine. Neuropharmacology 20:1067–1072
Durden D, Philips SR (1980) Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain. J Neurochem 34:1725–1732
Gianutsos G, Chute S (1986) Pharmacological changes induced by repeated exposure to phenylethylamine. Pharmacol Biochem 25:129–134
Greenshow AJ, Dourish CT (1984) Differential aversive stimulus properties of β-phenylethylamine andd-amphetamine. Psychopharmacology 82:189–193
Hirabayashi M, Alam MR (1981) Enhancing effect of metham phetamine on ambulatory activity produced by repeated administration in mice. Pharmacol Biochem Behav 15:925–932
Ishibashi K, Matsumoto T, Hirano M, Hirano H, Nakamura K, Nakahara T, Uchimura H (1986) β-Phenylethylamine (PEA) induced behavioral sensitization and changes in monoamine metabolism in discrete rat brain regions. Neurochem Res 11:1799–1800
Jeste DV, Kleinman JF, Potkin SG, Luchins DJ, Weinberger DR (1982) Ex Uno Multi: subtyping the schizophrenic syndrome. Biol Psychiatry 17:199–222
Kokkinidis L, Anisman H (1980) Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation. Psychol Bull 88:551–579
König JFR, Klippel RA (1963) The rat brain: a stereotaxic atlas of the forebrain and lower parts of the brain. Williams and Wilkins, Baltimore
Kuroki T, Matsumoto T, Hirano M, Kagoshima H, Yao H, Uchimura H, Nakamura K, Nakahara T (1987) Long-lasting effects of systemically administered caerulein on monoaminergic neuronal pathways in rat brain. Neuropeptides 9:169–176
Kuroki T, Tsutsumi T, Hirano M, Matsumoto T, Uchimura H, Shiraishi A, Nakahara T (1988) Involvement of central dopaminergic neuron systems in beta-phenylethylamine (PEA)-induced behavioral sensitization of the rat. Psychopharmacology 96:S371
Murphy DL, Belmaker RT, Carpenter WT, Wyatt RJ (1977) Monoamine oxidase in chronic schizophrenia: studies of hormonal and their factors affecting enzyme activity. Br J Psychiatry 130:151–158
Nielsen JA, Chapin DS, Moore KE (1983) Differential effects ofd-amphetamine, β-phenylethylamine, cocaine and methylphenidate on the rat of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerebroventricular perfusates of rat. Life Sci 33:1899–1907
Nishikawa T, Mataga N, Takashima M, Toru M (1983) Behavioral sensitization and relative hyper-responsiveness of striatal and limbic dopaminergic neurons after repeated amphetamine treatment. Eur J Pharmacol 88:195–203
Paulos M, Tessel RE (1982) Excretion ofβ-phenylethylamine is elevated in human after profound stress. Science 215:1127–1129
Philips SR, Robson AM (1983) In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine. Neuropharmacology 22:1297–1301
Potkin SG, Karoum F, Chuang LW, Cannon-Spoor HE, Philips I, Wyatt RJ (1979) Phenylethylamine in paranoid chronic schizophrenia. Science 206:470–471
Robinson TE, Becker JB (1982) Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from stratal tissue in vitro. Eur J Pharmacol 85:253–254
Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157–198
Robinson TE, Jurson PJ, Bennett JA, Bentgen KM (1988) Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 462:211–222
Shiraishi A, Hirano M, Matsumoto T, Kagoshima H, Kuroki T, Uchimura H, Nakahara T, Ishibashi K (1987) Stereotyped behaviors and the reverse tolerance phenomenon induced by chronicβ-phenylethylamine administration in the rats. Jpn J Psychopharmacol 7:83–84
Szymanski HV, Naylor EW, Karoum F (1987) Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients. Biol Psychiatry 22:194–198
Ungerstedt U, Herrera-Marshitz M, Jungenelius U, Stahle L, Tossman U, Zetterstrom T (1982) Dopamine synaptic mechanisms reflected in studies containing behavioral recordings and brain dialysis. Adv Dopamine Res 37:219–231
Wallach MB (1974) Drug-induced stereotyped behaviors: similarities and differences. In: Usdin E (ed) Neuropsychopharmacology of monoamines and their regulatory enzymes. Raven Press, New York, pp 241–260
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuroki, T., Tsutsumi, T., Hirano, M. et al. Behavioral sensitization to beta-phenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat. Psychopharmacology 102, 5–10 (1990). https://doi.org/10.1007/BF02245736
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245736